UK Trial Reveals Surfactant Treatment Offers No Benefit for Severe Bronchiolitis in Infants
A landmark UK-led clinical trial has determined that surfactant treatment provides no additional benefit for infants with severe bronchiolitis requiring life support. The findings, published on March 21, 2026, in The Lancet Respiratory Medicine, challenge current practices and open new avenues for research into effective treatments for this common and sometimes life-threatening, respiratory illness affecting babies.
Understanding Bronchiolitis and Surfactant
Bronchiolitis, most often caused by respiratory syncytial virus (RSV), is the leading cause of hospital admissions for babies in the UK during winter. The virus infects the small airways in the lungs, causing inflammation and difficulty breathing. Babies with bronchiolitis can experience reduced levels of surfactant, a substance that helps keep the lungs open.
Surfactant is routinely used to assist premature babies breathe more easily, leading researchers to investigate whether it could also benefit infants hospitalized with bronchiolitis. The Bronchiolitis Endotracheal Surfactant Study (BESS) trial, the largest of its kind, aimed to answer this question.
The BESS Trial: A Comprehensive Study
The BESS trial, funded by the UKRI Medical Research Council (MRC) and National Institute for Health and Care Research (NIHR), along with support from Chiesi Farmaceutici SpA, involved 232 critically ill babies across 15 children’s hospitals in England, Scotland, and Northern Ireland. The study spanned six winter seasons, from 2019 to 2024, to capture a broad range of cases.
Despite the promising rationale, the trial found that surfactant did not reduce the time babies needed to be on a ventilator. Professor Calum Semple OBE, lead researcher from the University of Liverpool and Alder Hey Children’s NHS Foundation Trust, stated the treatment was safe but “didn’t make any difference to how long babies stayed on ventilators.”
Implications for Future Treatment Strategies
While the BESS trial results are not what researchers hoped for, they provide crucial clarity. The findings emphasize the need to shift focus towards exploring alternative and targeted treatments for bronchiolitis. Researchers emphasize that surfactant therapy remains essential for premature newborn babies.
The study highlights the importance of preventative measures. Professor Semple urges expectant mothers to accept the offer of the RSV vaccine during pregnancy, which can protect their newborns from severe bronchiolitis.
The Role of Funding and Research Institutions
The success of the BESS trial underscores the vital role of research funding organizations like the MRC, and NIHR. These institutions support the evaluation of interventions with the potential to significantly improve health outcomes. The MRC, established in 1913, has a long history of groundbreaking medical discoveries, including contributions to our understanding of vitamins, DNA structure, and the link between smoking and cancer.
Looking Ahead: Emerging Research and Opportunities
The NIHR is actively funding research to improve the health and wealth of the nation, focusing on translating discoveries into improved treatments and services. Funding opportunities are available, such as the £4.7 million grant for the National PET Imaging Platform Data Platform, opening on April 1, 2026.
FAQ
Q: What is bronchiolitis?
A: Bronchiolitis is a common respiratory infection that affects babies and young children, causing inflammation of the small airways in the lungs.
Q: What is surfactant and why is it used?
A: Surfactant is a substance that helps keep the lungs open. It’s routinely used to help premature babies breathe more easily.
Q: Does this mean surfactant is never used for babies with breathing problems?
A: No. Surfactant remains an essential treatment for premature newborn babies. This study specifically looked at its leverage in infants with severe bronchiolitis already requiring life support.
Q: What can parents do to protect their babies from bronchiolitis?
A: The RSV vaccine offered to pregnant women is a key preventative measure. Good hygiene practices, such as frequent handwashing, can also help reduce the risk of infection.
Did you know? Bronchiolitis affects approximately 25,000 babies in the UK each year, with around 1,000 requiring intensive care.
Pro Tip: If your baby is experiencing difficulty breathing, seek immediate medical attention.
Stay informed about the latest advancements in pediatric respiratory health. Explore additional resources on the Medical Research Council website and the National Institute for Health and Care Research website.
What are your thoughts on this new research? Share your comments below!
